Structure for Curriculum Vitae



Curriculum Vitae

Jeffrey Nathan Rottman, MD

Professor of Medicine, Department of Medicine

University of Maryland School of Medicine

Date November 19, 2015

Contact Information

Division of Cardiovascular Medicine

University of Maryland School of Medicine

10 N. Greene Street, Room 5d-141

Baltimore, MD 21201

Cell: 615-887-5527

Clinical: 410-605-7000

Fax: 615-936-1724

Email: jrottman@medicine.umaryland.edu, jeffrey.rottman@, jeff@rottman.us

Foreign Languages: German (working knowledge)

Education

Undergraduate

1972-73 Johns Hopkins University, Baltimore, MD,

1973-76 AB Mathematics, summa cum laude

Princeton University, Princeton, NJ,

Graduate

1976-78 MA Mathematics

University of California, Berkeley, CA

Medical

1978-82 MD Columbia University, College of Physicians and Surgeons, New York, NY

Post Graduate Education and Training

Internship and Residency

1982-85 Intern, Resident and Senior Resident in Medicine,

Massachusetts General Hospital, Boston, MA

Fellowships

1985-87 Clinical and Research Fellow in Medicine (Cardiology)

Massachusetts General Hospital, Boston, MA

1987-89 Clinical and Research Fellow in Medicine (Cardiac Electrophysiology)

Massachusetts General Hospital, Boston, MA

1988-91 Bugher Research Fellow,

Laboratory of Molecular Cardiology,

The Children's Hospital, Boston, MA

Dr. Bernardo Nadal-Ginard

1991-92 Post-doctoral Fellow,

Molecular Biology and Pharmacology,

Washington University School of Medicine, St. Louis, MO

Dr. Jeff Gordon

Certifications

1983 National Board of Medical Examiners, Certificate 260117

1985 American Board of Internal Medicine (Valid indefinitely)

1987 Subspecialty Board in Cardiovascular Disease (valid indefinitely)

1988 Certificate of Special Competency in Pacing, North American Society for Pacing and Electrophysiology (NASPE)

1992 Subspecialty certification, Clinical Cardiac Electrophysiology,

Recertified 2002, 2012; Valid to 2022

Medical Licensures

1984 Massachusetts Medical License (not renewed 1991)

1991 Missouri Medical License (not renewed 1997)

1997 Tennessee Medical License

2015 Maryland

Employment History

Academic Appointments

1989-91 Instructor in Medicine, Harvard Medical School,

1991-97 Assistant Professor of Medicine, Washington University.

1997-04 Associate Professor of Medicine, Vanderbilt University

1998-04 Associate Professor of Pharmacology, Vanderbilt University

2004-15 Professor of Medicine and Pharmacology, Vanderbilt University

2015- Professor of Medicine, University. Maryland

Other Employment

Hospital Appointments

1989-91 Clinical Assistant in Medicine (Cardiology),

Massachusetts General Hospital, Boston, MA

1997-2015 Cardiologist / Electrophysiologist,

Vanderbilt University Hospital,

Nashville, TN

1997-2015 Cardiologist / Electrophysiologist,

Tennessee Valley VA Health Care System,

Nashville, TN

2015-present Cardiologist / Electrophysiologist,

University of Maryland Medical System

Baltimore, Maryland

2015-present Cardiologist / Electrophysiologist,

VA Maryland Health Care System

Baltimore, MD

Professional Society Memberships

1979-present Heart Rhythm Society, member

2002-present American Heart Association

Honors and Awards

1976 summa cum laude in mathematics, Princeton University

1976 Phi Beta Kappa, Princeton University

1981-1982 NSF Graduate Fellowship in mathematics

1982 David Scharf Scholarship, N.Y. Academy of Medicine

1982 Janeway Prize

Columbia University College of Physicians & Surgeons

1982 Stevelman Award in Cardiology

Columbia University College of P & S

1982 Bartlestone Award in Pharmacology

Columbia University College of P & S

1982 Alpha Omega Alpha, Columbia University College of P & S

1988-1990 Bugher Fellow, American Heart Association

1990-1995 NIH Physician-Scientist Award

2012, 2013 USNWR Top Doctors

2014, 2015 USNWR Top Doctors

Administrative Service

Institutional Service

1991-97 Director of Pacemaker Services, Jewish Hospital of St. Louis at Washington University Medical Center St. Louis, MO

1992-97 Human Studies Committee, Jewish Hospital, St. Louis

1993-97 Director, Arrhythmia Service, Jewish Hospital of St. Louis at

Washington University Medical Center St. Lous, MO

1997-present Director, Cardiac Electrophysiology, Nashville VA Medical Center

1999-04 Director, Atrial Fibrillation Center,

Vanderbilt Page-Campbell Heart Institute

1999-06 Acting Director, Cardiac Catheterization Laboratories,

Nashville VA Medical Center

2001-present Cardiology Division Clinical Compliance Liaison,

Vanderbilt University Medical Center

2001-present Scientific Steering Committee, Mouse Metabolic Physiology Center

2003-04 Chief (interim), Cardiology, Nashville VA Medical Center

2004-2015 Chief, Cardiology,

Nashville VA Medical Center

2005-09 Director, Clinical Cardiac Electrophysiology Fellowship Program

Vanderbilt University School of Medicine

2007-08 Research and Development Committee, Nashville VAMC,

Member

2008-2015 Research and Development Committee, Nashville VAMC, Chair

2008-2015 Middle Tennessee Research Institute (VA Non-profit research corporation), Board Member

2015-present Chief, Electrophysiology,

Baltimore VA Medical Center

2015-present Associate Director, Medical Care Center,

Baltimore VA

National (Committees, Councils, Task Forces)

1994-1996 Task Force on Heart Rate Variability, European Society of Cardiology and

North American Society of Pacing and Electrophysiology

Editorial Tasks

Ad hoc:

2005-present

American Journal of Physiology; American Heart Journal; American Journal of Cardiology; Circulation; Circulation Research; Journal of the American College of Cardiology; Journal of the American Society of Echocardiography; Journal of Biological Chemistry; Journal of Clinical Electrophysiology; British Heart Journal; Proc. Natl Acad Sci USA; Journal of Applied Physiology; Am Journal Physiology (Heart; Metabolism); Heart Rhythm; J Innov Cardiac Rhythm Management; PACE

Board:

2012-present Cardiovascular Engineering and Technology (BMES)

2014-present Associate Editor: Arrhythmia Grand Rounds (Heart Rhythm Society)

2011-present Section Editor, Arrhythmia: E-Medicine

Review Panels

Ad hoc:

1994, 1998, 1999 NIH

1998-1999 American Heart Association (MO),

American Heart Association (TN),

DRTC (Washington University),

Jewish Hospital Research Foundation (Washington University)

2000, 2002, 2003, 2004, 2006, 2007

Integrated Physiology Panel, National Space Biomedical Research Foundation (NASA),

2008 ZonMW (Netherlands)

2008, 2009 MicroMouse (NIDDK/MMPC)

Patents

1994 Method of screening for compounds with ability to alter apolipoprotein A1 gene expression, 5721096, S.K. Karathanasis, John A.A. Ladias, Jeffrey N. Rottman, Russell L. Widom

Teaching Service

Teaching and lectures (current and recent)

1999-present Cardiology Arrhythmia Teaching Conference, 42 sessions/year,

Vanderbilt University School of Medicine

1999-present

1999-present Cardiology Case Management Conference, 1-2 sessions/year

Vanderbilt University School of Medicine

1999-present

2012-present Intersession Arrhythmias in Cardiology (Medical School Course)

Vanderbilt University School of Medicine

Extended (3 hr) lecture on Medical Devices, Sudden Cardiac Death,

Conflicts of Interest in Clinical Investigation

2010-present Medical Device lectures, Medical Drugs and Devices Course

Masters of Science in Clinical Investigation (MSCI)

Vanderbilt University School of Medicine

Annual Extended Lecture

TRAINEES

Cardiology Fellows, Laboratory

1992-1993 Jose Rosado, MD, Washington University

1993-1995 Errol Williams, MD, Washington University

Undergraduates, Laboratory

1996-1997 Lyn Kuo, Washington University (Honors thesis)

Electrophysiology Fellows

1996-1997 Martin Emert, MD, Washington University

1996-1997 Greg Botterton, MD, Washington University

1996-1997 Mitchell Faddis, MD, PhD, Washington University

1997-1998 Mark Kovacs, MD, Vanderbilt University

1998-1999 Joe Kureya, MD, Vanderbilt University

1998-1999 Alexander Mazur, MD, Vanderbilt University

1999-2001 T. David Gbadebo, MD, Vanderbilt University

2000-2002 W. David Thompson, MD, Vanderbilt University

2001-2003 R. Andrew Pickett, MD, Vanderbilt University

2002-2004 Muhammed Ali, MD, Vanderbilt University

2004-2006 Carmine Oddis, MD, PhD, Vanderbilt University

2003-2006 Andrew Smith, MD, Vanderbilt University

2005-2007 Michelle Khoo, MBBS, Vanderbilt University

2005-2007 Yingbo Yang, MD, PhD, Vanderbilt University

2007-2008 Robert Abraham, MD, Vanderbilt University

2007-2008 Christopher Ellis, MD, Vanderbilt University

2008-2010 Juan Carlos Estrada, MD, Vanderbilt University

2008-2010 Bradley Hardin, MD, Vanderbilt University

2008-2010 Shane Rowan, MD, Vanderbilt University

2010-2011 Nagesh Chopra, MBBS, Vanderbilt University

2009-2011 Joseph Vaglio, MD, Vanderbilt University

2010-2012 Jason Rytlewski, MD, Vanderbilt University

2011-2012 Randy Nagarakanti, MD, Vanderbilt University

2011-2012 Sunthosh Parvathenani, MD, Vanderbilt University

2012-2014 Michael Bestawros, MD, MPH, Vanderbilt University

2012-2014 Sandeep Goyal, MBBS, Vanderbilt University

2012-2014 Jessica Delaney, MD, Vanderbilt University

2013-2015 Moore Benjamin Shoemaker, MD, Vanderbilt University

Grants

Active

09/30/09 – 06/30/16 Jeffrey Rottman (Core Consultant, as needed; PI - Hatzopoulos)

NHLBI Progenitor Cell Biology Consortium

Optimizing Cardiovascular Stem Cells for Cardiac Repair and Regeneration

NIH/NHLBI 1U01 HL100398

Institutional participation with a total of nine research hubs to study the biology of blood, lung and heart progenitor cells.

2011-2016 Jeffrey Rottman (Co-Director Cardiovascular Pathophysiology, AN-10%: PI-Wasserman)

Vanderbilt Mouse Metabolic Physiology Centers

NIH/NIDDK U24 DK59637

Annual Direct Costs: 600,000

Total Direct Costs: $2,979,000 (cardiovascular core ~ 25%)

The goal of this program is to provide centers for advanced phenotyping for murine models of metabolic disease, including extensive cardiovascular characterization.

2014-present Jeffrey Rottman (Executive Committee, 6.725%; PI-S Singh)

Safety and Efficacy of ICDs in the Elderly, VA Cooperative Studies Program CSP 592

Annual Direct Costs: 600,000 (pilot phase)

Annual Direct Costs (VA CSP Program, full study): 4,200,000

VA cooperative study evaluating whether ICD's are effective for primary prevention in a specific elderly population.

2015 Jeffrey Rottman (Site PI (Nashville TVHS) 6.725%; PI-S Singh)

Safety and Efficacy of ICDs in the Elderly, VA Cooperative Studies Program CSP 592

Site Annual Direct Costs: 140,000

Total Direct Costs: 280,000 (2 year pilot phase)

VA cooperative study evaluating whether ICD's are effective for primary prevention in a specific elderly population.

2012-2015 Jeffrey Rottman (PI, as-needed %)

Training Site for Lead Extraction.

Sponsor: Spectranetics

Annual Direct Costs: $12,000-$20,000

Total Direct Costs: $36,000-$60,000

Vanderbilt serves as a specialized training site for excimer laser lead extraction, a program mandated by FDA requirements. Trainees are hosted for structured didactic and observational activity over a several day period.

Inactive

1981-1982 Graduate Fellowship in Mathematics, National Science Foundation

1987-1992 Heart Rate Variability in Patients After Myocardial Infarction Consultant, Consultant (PI - J. T. Bigger, Jr), HL41552

1988-1991 Bugher Fellowship for Molecular Biology Research, American Heart Association,

1990-1995 Nuclear hormone receptors in cardiac gene regulation, Physician Scientist Award, PI, K11 HL02488

1990-1998 The CABG Patch Study, PI for Jewish Hospital

(1990-1997), Co-chair, Quality Control Subcommittee

(1990-1997), (Study PI - J. T. Bigger, Jr., Columbia University), HL-48159

1992-1994 Safety and efficacy of Telectronics Guardian II ICD, Telectronics

1992-1994 Use of NAPA for treatment of atrial fibrillation, IBRD

1992-1997 Multicenter automatic defibrillator implantation trial (MADIT), CPI/Guidant, PI for Jewish Hospital (PI for study - A. Moss, U. Rochester)

1993-1995 Electrophysiologic efficacy of d-sotalol, Bristol-Myers-Squibb

1994-1998 Placebo controlled evaluation of the efficacy and safety of oral sotalol in patients with life threatening ventricular arrthymias and implanted cardioverter-defibrillators, Berlex Laboratories, PI for Jewish Hospital

1995-1997 Transcriptional regulation of cardiac fatty acid binding protein, American Heart Association (Missouri Affiliate) Grant-in-aid

1995-1998 Changes in heart rate variability in CAST, R03HL53776, Consultant (Robert Kleiger, P.I.)

1996-1997 Lipid binding specificity and protein-protein interactions of heart fatty acid binding protein, Jewish Hospital Research Foundation

1996-1999 Regulation of cardiac fatty acid protein message, PI, American Heart Association (National) Grant-in-aid

1999-2001 Endothelial fatty acid binding protein: regulation and function. 1/1/99 – 12/31/01, PI, Pilot application, CNRU, DK26657

1998-2000 Clinical evaluation of the RES-Q arrhythmia control device, Intermedics, PI for Jewish Hospital Energy Safety Study (LESS), CPI/Guidant, PI, Vanderbilt Univ

1998-2000 Model 7250 Arrhythmia Management Device, Medtronic, PI, Vanderbilt University

1998-2000 Effects of thiazolidiones on cardiovascular gene expression, Co-PI (with DE Vaughan) Warner-Lambert 980285

1999-2002 Heart fatty acid binding protein, diabetes, and cardiac lipid metabolism, PI, American Heart Association (National) Grant-in-Aid

2000-2002 A Cell Culture Model of Atrial Fibrillation, co-PI (with K. Murray), P&G

2000-2002 IV Amiodarone for Atrial Fibrillation after Cardiac Surgery (PAACT), Wyeth-Ayerst, PI (also J. Balser, D. Drinkwater)

2000-2008 Atrial Fibrillation Center, Infrastructure Support, Various Industrial

2001-2004 Standard/Left-ventricular based cardiac stimulation post AV node ablation (PAVE), St. Jude, PI

2001-2004 Reduced incidence and duration of AF/AT with the Jewel AF (RID AF), Medtronic, PI

2001-2002 Safety and Efficacy of CVT 4123, An Intravenous Agent for the Acute Control of Rate in Atrial Fibrillation, CV Therapeutics

2001-2004 Evaluation of Dual vs. Single Chamber Defibrillator Outcome (DAVID), St. Jude, PI/co-PI, VAMC/VUH

2002-2004 Left Ventricular-Based Cardiac Stimulation Post AV Node Ablation Evaluation (PAVE), St. Jude Medical, PI

2003-2007 Search AV Extension for Promoting Atrioventricular Conduction (SAVE PACe), Medtronic, PI

2004-2008 Inhibition of Unnecessary RV Pacing with AV Search Hysteresis in ICD’s – INTRINSIC RV, Guidant, PI

2000-2005 Vanderbilt Mouse Metabolic Physiology Centers, Vascular Pathophysiology Core Associate Director, Vascular Pathophysiology Core, U24 DK59637

2003-2006 Tissue Glucose and Fatty Acid Uptake in Conscious Mouse Models of Insulin Resistance, Principal Investigator, Medical Research Service, Department of Veterans Affairs

2004-2007 Phenotypic and Genotypic Prediction of Anti-Arrhythmic Therapy with ICD’s Principal Investigator, Medical Research Service, Department of Veterans Affairs

2005-2006 Vanderbilt Mouse Metabolic Physiology Centers, Cardiovascular Pathophysiology Core Director, Vascular Pathophysiology Core, U24 DK59637

2007-2009 Arrhythmias and the Metabolic Syndrome, Medtronic, Principal Investigator (Investigator initiated) Medtronic Center of Excellence, Vanderbilt University School of Medicine,

2006-2012 Role of Bves in Cardiac Development, Consultant, NIH/NHLBI, R01 (David Bader, PI)

2009-2013 Stem Cell Consortium in Cardiovascular Therapy, NIH/NHLBI U01, Co-Investigator (Douglas Vaughan, Vanderbilt Principal Investigator)

2007-2011 LEK1 in Coronary Vascularization, Consultant, NIH/NHLBI R01, (David Bader, PI)

2007-2012 Fish Oil in Atrial Fibrillation, Data Safety and Monitoring Board, NIH/NHLBI R01 (C. Michael Stein, PI)

2006-2008 ReLY Trial (Warfarin/Dabigatran), Boehringer, Principal Investigator, Vanderbilt University

2009-2013 Creating Super Stem Cells for Cardiac & Wound Repair NIH/NHLBI L88424 (P Young, PI), Co-Investigator. The goal of this program is to investigate genetically modified stem cells for cardiac repair. I participate in the evaluation of in vivo cardiac phenotype.

2011-2013 Executive Planning Committee, ICD's in the Elderly, VA Cooperative Studies Program (S Singh, PI) Planning for a VA cooperative study evaluating whether ICD's are effective for primary prevention in a specific elderly population.

2012-2013 Vitals Chair: Improving Diagnosis of Cardiovascular Disease in Sub-Saharan Africa, Vanderbilt Heart and Vascular Institute Technology Innovation Grant, M Bestawros and J Rottman

Publications

Peer-reviewed journal articles

Original Investigations

1. Weld FM, Coromilas J, Rottman JN, Bigger JT Jr: Mechanisms of quinidine-induced depression of maximum upstroke velocity in ovine cardiac Purkinje fibers. Circulation Research 50: 369-76 (1982)

2. Leahey EB Jr, Bigger JT Jr, Butler VP, Reiffel JA, O'Connel GC, Scafidi L, Rottman JN: Quinidine-digoxin interaction: time course and pharmacokinetics. Am J Cardiology 48:1141-6 (1983)

3. Kuchar DL, Rottman J, Berger E, Freeman CS, Garan H, Ruskin J: Prediction of successful suppression of sustained ventricular arrhythmias by serial drug testing from data derived at initial electrophysiologic study. J Am College Cardiology 12: 982-8 (1988)

4. Carlson M, Palacios I, Thomas JD, Rottman J, Freeman CS, Block PC, Garan H, Ruskin JN: Conduction abnormalities during percutaneous balloon mitral or aortic valvuloplasty. Circulation 79: 1197-1203 (1989)

5. Bigger JT Jr, La Rovere MT, Steinman RC, Fleiss JL, Rottman JN, Rolnitzky LM, Schwartz PJ: A comparison of baroreflex responsiveness and heart period variability after myocardial infarction. J Am College Cardiology 14:1511-1518 (1989)

6. Kuchar DL, Garan H, Venditti FJ, Finkelstein D, Rottman JN, McComb J, McGovern BA, Ruskin JN: Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarction. Am J Cardiology 64: 33-36 (1989)

7. Rottman JN, Thompson WR, Nadal-Ginard B, Mahdavi V: Myosin heavy chain gene expression: Interplay of cis and trans factors determines hormonal and tissue specificity. Symposium proceedings on The Dynamic State of Muscle Fibers, Walter de Gruyter & Co, Berlin (1990)

8. Rottman JN, Steinman RC, Albrecht P, Bigger JT Jr, Rolnitzky LM, Fleiss JL: Efficient estimation of the heart period power spectrum suitable for physiologic or pharmacologic studies. Am J Cardiology 66:1522-4 (1990)

9. Rottman JN, Widom RL, Nadal-Ginard B, Mahdavi V, Karathanasis SK: Retinoic acid response elements from apolipoprotein A1 distinguishes two different retinoic acid response pathways. Molecular & Cellular Biology 11:3814-20 (1991)

10. Bigger JT Jr, Fleiss J, Steinman R, Rolnitzky L, Kleiger RE, Rottman JN: Frequency domain measures of heart period variability and mortality two weeks after myocardial infarction. Circulation 85: 164-71 (1992)

11. Bigger JT Jr, Fleiss J, Steinman R, Rolnitzky L, Kleiger RE, Rottman JN: Correlations among time and frequency domain measures of heart period variability measured two weeks after myocardial infarction. Am J Cardiology 69:891-8 (1992)

12. The CABG Patch Trial Investigators and Coordinators: The Coronary Artery Bypass Graft (CABG) Patch Trial. Progress in Cardiovascular Disease 36:97-114 (1993)

13. Brachmann J, Freigang K, Saggau W, CABG Patch Trial Investigators and Coordinators. The Coronary Artery Bypass Graft (CABG) Patch Trial. PACE 16:571-575 (1993)

14. Goldsmith RL, Bloomfield D, Rottman JN, Bigger JT Jr: Heart rate variability: disagreement on the markers of sympathetic and parasympathetic activities. J Am College Cardiology 22:952-953 (1993)

15. Rottman JN, Gordon JI: Comparison of the patterns of expression of rat intestinal fatty acid binding protein/human growth hormone fusion genes in cultures intestinal epithelial cell lines and in the gut epithelium of transgenic mice. J Biological Chemistry 268:11994-12002 (1993)

16. Stein PK, Rottman JN, Bosner, MS, Conger BM, Kleiger RE. Effects of pindolol and labetalol on heart rate variability in normal subjects. J Ambulatory Monitoring 8:171-178 (1995)

17. Stein PK, Rottman JN, Kuru T, Kleiger RE. Effect of moricizine on heart rate variability in normal subjects. Int J Cardiology 48:59-65 (1995)

18. Stein PK, Rich MW, Rottman JN, Kleiger RE. Stability of indices of heart rate variability in patients with congestive heart failure. Am Heart J. 129:975-981 (1995)

19. Zaim S, Zaim B, Rottman J, Mendoza I, Nasir N, Pacifico A, and Cadence Investigators. Sudden cardiac death survivors with only ventricular fibrillation induction at baseline electrophysiologic testing: subsequent ventricular arrhythmias. Proceedings of Euro-Pace '95-7th European Symposium, pp. 27-30. Monduzzi Editore S.p.A. Bologna, Italy 1995.

20. Williams E, Halpert I, Wickline S, Davison G, Parks W, Rottman J. Osteopontin expression is increased in the heritable myopathy of Syrian hamsters. Circulation 92:705-709 (1995)

21. Task Force on Standards of Heart Rate Variability. Heart Rate Variability: Standards of Measurement, physiological interpretation, and clinical use. Annals of Non-invasive Electrocardiology 1:151-181 (1996)

22. Task Force on Standards of Heart Rate Variability. Heart Rate Variability: Standards of Measurement, physiological interpretation, and clinical use. Circulation. 93:1043-1065 (1996)

23. Stein PK, Rottman JN, Hall AE, Kleiger RE. Heart rate variability in a case of pheochromocytoma. Clinical Autonomic Res. 6:41-44 (1996)

24. Stein PK, Rottman JN, Kleiger RE. Effect of transdermal nicotine patches and smoking cessation on heart rate variability. Am. J. Cardiology 77:701-705 (1996)

25. Arlt MF, Goodfellow PJ, Rottman JN. Dinucleotide repeat in the third intron of the FABP3/MDGI putative tumor suppressor gene. Disease Markers 13:57-59 (1996)

26. Zaim S, Zaim B, Rottman J, Mendoza I, Nasir N, Pacifico A, Cadence Investigators. Characterization of spontaneous recurrent ventricular arrhythmias dectected by electrogram storing defibrillators in sudden cardiac death survivors without inducible ventricular tachyarrhythmias at baseline electrophysiologic testing. Am. Heart J. 132:274-9 (1996)

27. Moss AJ et al. For the MADIT Investigators. Improved survival in patients with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmias. New England J. Med. 335:1933-7 (1997)

28. Stein PK, Kleiger RE, Rottman JN. Differing effects of age on heart rate variability in men and women. Am. J. Cardiology 80:302-305 (1997)

29. Bigger JT, Jr, CABG Patch Trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. New England J. Med. 337:1569-75 (1997)

30. Stein PK, Nelson P, Rottman JN, Howard D, Ward SM, Kleiger RE, Senior RM. Heart rate variability reflects severity of COPD in Pi-Z alpha-1 antitrypsin deficiency. Chest 113:327-333 (1998)

31. Hogue CW, Domitrovich PP, Stein PK, Despotis GD, Re L, Schuessler RB, Kleiger RE, Rottman JN. RR interval dynamics prior to atrial fibrillation in patients after coronary artery bypass graft surgery. Circulation 98:429-434 (1998)

32. Zhang S, Watson N, Zahner J, Rottman JN, Blumer KJ, Muslin AJ. RGS3 and RGS4 are GTPase activating proteins in the heart. J. Mol. Cell. Cardiol. 30:269-276 (1998)

33. Stein PK, Ehsani AA, Domitrovich PP, Kleiger RE, Rottman JN. Effect of exercise training on heart rate variability in healthy older adults. American Heart J. 138:567-76 (1999)

34. Bigger, JT Jr, DiMarco JP, Rottman JN. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery New England Journal of Medicine 338:1227 (1998)

35. Stein PK, Hagley MT, Cole PL, Domitrovich PP, Kleiger RE, Rottman JN. Changes in 24-hour heart rate variability during normal pregnancy. Am. J. Obstetrics Gyn. 180:978-985 (1999)

36. Qian Q, Kuo L, Yu Y-T., Rottman, JN. A concise promoter region of the heart fatty acid binding protein gene dictates tissue-appropriate expression. Circulation Research 84:276-289 (1999).

37. Rottman JN, Levin B, Parides M, Tsai J, Bigger JT, Jr. Using missing data techniques to explore the lack of effect in The CABG Patch Trial. Statistics in Medicine 18:1943-59 (1999)

38. Bigger JT, Jr., Whang W, Rottman JN, Kleiger RE, Gottlieb CD, Namerow PB, Steinman RC, Estes N, III. Mechanisms of death in The CABG Patch Trial: A randomized trial of implantable cardiac defibrillator prophylaxis in patients at high risk of death after coronary artery bypass graft surgery. Circulation 99:11416-141 (1999)

39. Bilge AR, Stein PK, Domitrovich PP, Gerard PL, Rottman JN, Kleiger RE, Kulbertus HE, Pierard LA. Assessment of ultra low frequency heart rate variability: Validation of alternative methods. Int. J. Cardiol. 71:1-6 (1999).

40. Antonio Pacifico, et al for the d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. Prevention of implantable-defibrillator shocks by treatment with sotalol. New England Journal of Medicine 340:1855-1862 (1999)

41. VanderLugt JT, et al for the Ibutilide Investigators. Efficacy and safety of ibutilide fumarate for the conversion of atrial arrhythmias after cardiac surgery. Circulation 100:369-75 (1999)

42. Stein PK, Domitrovich PP, Kleiger RE, Schectman, KB, Rottman JN for the CAST Investigators. Clinical and demographic predictors of heart rate variability in The Cardiac Arrhythmia Suppression Trial. Clinical Cardiology 23:187-194 (2000)

43. Stein PK, Carney RM, Freedland KE, Skala JA, Jaffe AS, Kleiger RE, Rottman JN. Severe depression is associated with markedly reduced heart rate variability in patients with stable coronary heart disease. J Psychosom Res. 48:493-500 (2000).

44. Rottman JN, Bracy D, Malabanan C, Yue Z, Clanton J, Wasserman DH. Contrasting Effects Of Exercise And Nitric Oxide Synthase Inhibition On Tissue-Specific Fatty Acid And Glucose Uptake In Mice. Am. J. Physiol Endo. Metab 283:E116-123 (2002)

45. Kannankeril P, Anderson ME, Rottman JN, Wathen MS, Fish FA. Infrequent late recurrence of intraatrial reentry tachycardia following radiofrequency catheter ablation in patients with congenital heart disease. Am J. Cardiol. 92:879-881 (2003)

46. Rottman JN, Ni G, Khoo M, Wang Z, Zhang W, Anderson ME, Madu EC. Temporal Changes in Ventricular Function Assessed Echocardiographically in Conscious and Anesthetized Mice. J. American Society of Echocardiography 16:1150-1157 (2003)

47. Exil VJ, Roberts RL, Sims H, McLaughlin JE, Malkin RA, Gardner CD, Ni G, Rottman JN, Strauss AW. Cardiomyopathy in the Very-Long-Chain Acyl-CoA Dehydrogenase Deficient Mouse. Circulation Research 93:448-455 (2003)

48. Shearer J, Fueger PT, Vorndick B, Bracy DP, Rottman JN, Clanton JA, Wasserman DH. AMP Kinase-Induced Skeletal Muscle Glucose But not Long-Chain Fatty Acid Uptake is Dependent on Nitric Oxide. Diabetes 53:1429-35 (2004)

49. Pickett III, RA, Saavedra P, Ali MF, Darbar D, Rottman JN. Implantable Cardioverter Defibrillator Malfunction from Mechanical Failure of the Header Connection. J. Clin. Electrophysiol. 15:1095-1099 (2004)

50. Shearer J, Fueger PT, Rottman JN, Bracy DP, Martin PH, Wasserman DH. AMPK Stimulation Increases LCFA but not Glucose Clearance in Cardiac Muscle In Vivo. Am J Physiol Endocrinol Metab 287:E871-7. (2004)

51. Murray KT, Rottman JN, Arbogast PG, Shemanski L, Primm RK, Campbell WB, Solomon AJ, Olgin JE, Wilson MJ, Dimarco JP, Beckman KJ, Dennish G, Naccarelli GV, Ray WA; the AFFIRM Investigators. Inhibition Of Angiotensin II Signaling And Recurrence Of Atrial Fibrillation In AFFIRM. Heart Rhythm Heart Rhythm 1:669-75 (2004)

52. Shearer J, Fueger PT, Rottman JN, Bracy DP, Binas B, Wasserman DH. Heart-Type Fatty Acid Binding Protein Reciprocally Regulates Glucose and Fatty Acid Utilization during Exercise. Am J Physiol Endocrinol Metab. 288:E292-7 (2005)

53. Yang Z, Shen W, Rottman JN, Wikswo JP, Murray KT. Rapid stimulation causes electrical remodeling in cultured atrial myocytes. J Mol Cell Cardiol. 38:299-308 (2005)

54. Kozlov S, Mounkes L, Cutler D, Sullivan T, Hernandez L, Levy N, Rottman J, Stewart CL. Mutations in the mouse Lmna gene causing progeria, muscular dystrophy and cardiomyopathy. Novartis Found Symp. 264:246-58; 258-63 (2005).

55. Fueger PT, Shearer J, Krueger TM, Posey KA, Bracy DP, Heikkinen S, Laakso M, Rottman JN, Wasserman DH. Hexokinase II protein content is a determinant of exercise endurance capacity in the mouse. J Physiol. 566:533-541 (2005)

56. Mounkes LC, Kozlov SV, Rottman JN, Stewart CL. Expression of an LMNA-N195K variant of A-type lamins results in cardiac conduction defects and death in mice. Hum Mol Genet 14:2167-2180 (2005)

57. O’Donnell SM, Hansberger MW, Connolly JL, Chappell JD, Watson MJ, Pierce JM, Wetzel JD, Han W, Barton ES, Forrest JC, Valvy-Nagy T, Yull FE, Blackwell TS, Rottman JN, Sherry B, Dermody TS. Organ-specific roles for transcription factor NF-kB in reovirus-induced apoptosis and disease. J. Clin Invest 115:2341-2350 (2005)

58. Shearer J, Fueger PT, Bracy DP, Wasserman DH, Rottman JN. Partial gene deletion of heart-type fatty acid-binding protein limits the severity of dietary-induced insulin resistance. Diabetes 54:3133-9 (2005)

59. Temple J, Frias P, Rottman J, Yang T, Wu Y, Verheijk EE, Zhang W, Siprachhanh C, Kanki H, Atkinson JB, King P, Anderson ME, Kuperschmidt S, Roden DM. Atrial fibrillation in KCNE1-null mice. Circ Res 97:62-69 (2005)

60. Exil VJ, Gardner, CD, Rottman JN, Sims H, Bartelds B, Khuchua Z, Sindhal R, Ni G, Strauss AW. Abnormal mitochondrial bioenergetics and heart rate dysfunction in mice lacking very-long-chain acyl-CoA dehydrogenase. Am J Physiol Heart and Circulatory 290:H1289-97 (2006)

61. Melcon G, Kozlov S, Cutler DA, Sullivan T, Hernandez L, Zhao P, Mitchell S, Nader G, Bakay M, Rottman JN, Hoffman EP, Stewart CL. Loss of emerin at the nuclear envelope disrupts the Rb1/E2F and MyoD pathways during muscle regeneration. Hum Mol Genet 15: 637-51 (2006)

62. Rottman JN, Ni G, Brown M. Echocardiographic Evaluation of Ventricular Function in Mice, Echocardiography 24:83-89 (2007)

63. Ayala JE, Bracy DP, Julien BM, Rottman JN, Fueger PT, Wasserman DH. Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. Diabetes 56:1025-33 (2007)

64. Fueger PT, Li CY, Ayala JE, Shearer J, Bracy DP, Charron MJ, Rottman JN, Wasserman DH. Glucose Kinetics and Exercise Tolerance in GLUT4 Null C57BL/6 Mice. J Physiol. 582:801-12 (2007)

65. Fueger PT, Lee-Young RS, Shearer J, Bracy DP, Heikkinen S, Laakso M, Rottman JN, Wasserman DH. Phosphorylation Barriers to Skeletal and Cardiac Muscle Glucose Uptakes in High Fat Fed Mice: Studies in Mice with a 50% Reduction of Hexokinase II. Diabetes. 56:2476-84 (2007)

66. Shearer J, Coenen KR, Pencek RR, Swift LL, Wasserman DH, Rottman JN. Long Chain Fatty Acid Uptake In Vivo: Comparison of [(125)I]-BMIPP and [ (3)H]-Bromopalmitate. Lipids 43:703-11 (2008)

67. Shearer J, Fueger PT, Wang Z, Bracy DP, Wasserman DH, Rottman JN. Metabolic implications of reduced heart-type fatty acid binding protein in insulin resistant cardiac muscle. Biochim Biophys Acta. 782:586-92 (2008)

68. Hebert PR, Coffey CS, Byrne DW, Scott TA, Fagard RH, Rottman JN, Murray KT, Oates JA. Treatment of Elderly Hypertensive Patients with Epithelial Sodium Channel Inhibitors Combined with a Thiazide Diuretic Reduces Coronary Mortality and Sudden Cardiac Death. J Am Soc Hypertension 2(5):355-365 (2008)

69. Alfaro MP, Pagni M, Vincent A, Atkinson J, Hill MF, Cates J, Davidson JM, Rottman J, Lee E, Young PP. The Wnt modulator sFRP2 enhances mesenchymal stem cell engraftment, granulation tissue formation and myocardial repair. Proc Natl Acad Sci U S A. 105:18366-71 (2008).

70. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 361:1139-51. (2009)

71. Ellis CR, Rottman JN. Increased rate of subacute lead complications with small-caliber implantable cardioverter-defibrillator leads. Heart Rhythm. 6:619-24 (2009)

72. Monahan K, Storfer-Isser A, Mehra R, Shachar E, Mittleman M, Rottman J, Punjabi N, Sanders M, Quan SF, Resnick H, Redline S. Triggering of nocturnal arrhythmias by sleep-disordered breathing events. J Am Coll Cardiol 54:1797-804 (2009)

73. Hughey CC, Alfaro MP, Belke DD, Rottman JN, Young PP, Wasserman DH, Shearer J. Increased oxygen consumption and OXPHOS potential in superhealer mesenchymal stem cells. Cell Regeneration (2012)

74. Rytlewski JA, Saavedra P, Rottman JN. Successful ICD Implantation in the Setting of RV Channel Noise, J of Innovations in Cardiac Rhythm Management 2:274-6 (2011)

75. Palmisano BT, Rottman JN, Wells QS, DiSalvo TG, Hong CC. Familial Evaluation for Diagnosis of Arrhythmogenic Right Ventricular Dysplasia, Cardiology 119:47-53 (2011)

76. Hughey CC, Johnsen VL, Ma L, James FD, Young PP, Wasserman DH, Rottman JN, Hittel DS, Shearer J. Mesenchymal Stem Cell Transplantation for the Infarcted Heart: A Role in Minimizing Abnormalities in Cardiac-Specific Energy Metabolism. Am J Physiol Endocrin. And Metab. 302:E163-72 (2012)

77. Ozcan C, Rottman JN, Heist EK, Guy ML, Ellinor PT, Singh J, Milan DJ, Danik SB, Barrett CD, Mansour M, Ruskin JN, Mela T. Unpredictable battery depletion of St Jude Atlas II and Atlas+ II HF implantable cardioverter-defibrillators. Heart Rhythm 9:717-20 (2012)

78. Dees E, Miller PM, Moynihan KL,, Pooley RD, Hunt RP, Galindo CL, Rottman JN, Bader DM. Cardiac-specific deletion of the microtubule-binding protein CENP-F causes dilated cardiomyopathy. Disease Models & Mechanisms. 4:468-80 (2012)

79. Nagarakanti R, Raj SR, Rottman JN. Pacing output failure after electrocautery during pulse generator replacement. J Innovations in Cardiac Rhythm Management 3:912-6 (2012)

80. Parvathenani SV, Ellis CR, Rottman JN. High Prevalence of Insulation Failure with Externalized Cables in St Jude Medical Riata Family ICD Leads: Fluoroscopic Grading Scale and Correlation to Extracted Leads. Heart Rhythm 9:1218-24 (2012)

81. Goyal SK, Ellis CR, Rottman JN, Whalen SP. Lead Thrombi Associated with Externalized Cables on Riata ICD Leads: A Case Series. J Cardiovasc Electrophysiol 24(9):1047-50 (2013)

82. Hughey CC, Ma L, James FD, Bracy DP, Wang Z, Wasserman DH, Rottman JN, Hittel DS, Shearer J. Mesenchymal stem cell transplantation for the infarcted heart: therapeutic potential for insulin resistance beyond the heart. Cardiovasc Diabetol 12:128 (2013) PMID: 24007410

83. Richardson TD, Kolek MJ, Goyal SK, Shoemaker MB, Lewis AA, Rottman JN, Whalen SP, Ellis CR. Comparative outcomes of transvenous extraction of Sprint Fidelis and Riata defibrillator leads: a single center experience. J Cardiovasc Electrophysiol 25(1):36-42 (2014) PMID: 24028661

84. Hughey CC, James FD, Ma L, Bracy DP, Wang Z, Wasserman DH, Rottman JN, Shearer J. Diminishing impairments in glucose uptake, mitochondrial content, and ADP-stimulated oxygen flux by mesenchymal stem cell therapy in the infarcted heart. Am J Physiol Cell Physiol. 306(1):C19-27 (2014) PMID: 24196528

85. Goyal SK, Ellis CR, Ball SK, Ahmad R, Hoff SJ, Whalen SP, Rottman J. High-Risk Lead Removal by Planned Sequential Transvenous Laser Extraction And Minimally Invasive Right Thoracotomy. J Cardiovasc Electrophysiol. 25(6):617-21 (2014) PMID:24446764.

86. Kolek M, Patel N, Clair W, Whalen S, Rottman J, Kanagasundram A, Shen S, Saavedra P, Estrada J, Abraham R, Ellis C. Efficacy of a Bio-absorbable Antibacterial Envelope to Prevent Cardiac Implantable Electronic Device Infections in High-Risk Subjects. J Cardiovasc Electrophysiol 26(10):1111-6 (2015) PMID: 26222980

87. Montgomery JA, Kanagasundram AN, Clair WK, Rottman JN, Crossley GH. Sudden Cardiac Death Despite a Functional Cardioverter-Defibrillator: The Casee for Early and Aggressive Therapy for Ventricular Teachuycardia in Selected Patients. J Cardiovasc Electrophysiol. (29 Oct 2015) PMID: 26511459

Reviews, Case Reports, Letters, Editorials

1. Kleiger RE, Bosner M, Rottman J, Stein P: The time domain measurement of heart rate variability. J Ambulatory Monitoring 6:1-18 (1993)

2. Rottman JN, Kleiger RE, Stein PK. Heart rate variability: Measurement and meaning. Cardiology in Review 4:101-111 (1996)

3. Khoo MSC, Scholl F, Dignan R, Rottman JN. Migration and Infection of a Pace-Sense Lead from an Abdominal Defibrillator System. PACE 25:1652-5 (2002)

4. Raj SR, Dendy JM, Rottman JN. Complete Superior Vena Cava Obstruction. J Am Coll Cardiol 55:e139 (2010)

5. Shoemaker MB, Rottman JN. Conductor Extrusion in a Persistent Left Superior Vena Cava. Europace 14:307 (2012)

6. Rottman J. Learning from implantable cardioverter-defibrillator leads in children. Circulation 127(24):2370-1 (2013) PMID: 23694967

7. Aznaurov S, Rottman JN. QuickSite CRT Lead Conductor Externalization: A Short Story,” Arrhythmia Grand Rounds (in press)

8. McGuinn E, O'Leary J, Crossley GH, Rottman JN. Emergent Use of an MRI-Conditional External Pacemaker in a Patient with Sinus Arrest Facilitating Diagnosis of a Temporal Lobe Neoplasm. Heart Rhythm Case Reports (in press)

Books and Book Chapters

1. Kleiger RE, Stein P, Bosner MS, Rottman JN: Time domain measures of heart rate variability. Cardiology Clinics of North America 10:487-998 (1992).

2. Kleiger RE, Stein P, Bosner MS, Rottman JN: Time domain measures of heart rate variability in Heart Rate Variability, M. Malik & A. J. Camm, eds, Futura, Armonk, NY (1995)

3. Rottman JN, Bigger JT Jr: Spectral analysis and heart rate variability, in Cardiac Arrhythmia: Mechanism, Diagnosis and Management. Williams and Wilkens, Baltimore (1995)

Other Brief Communications

1. Raj SR, Rottman JN. Risk Stratification Using Autonomic Testing: Blown up by DINAMIT? J Cardiovasc Electrophysiol. 2011 (letter)

Lectures

“Prevention of Sudden Cardiac Death,” Vanderbilt University School of Medicine, Medicine Grand Rounds, 1998

“Heart Rate Variability Panel Discussion,” NASPE (North American Society for Pacing and Electrophysiology), Scientific Sessions, 1998

“Cardiac Transcription (Session Moderator),” American Heart Association Annual Scientific Session, 1998

“Specific ICD Indications (Panel and Discussion),” American College of Cardiology Annual Scientific Sessions, 1999

“AF 2K: What’s New in Atrial Fibrillation,” Vanderbilt University School of Medicine, Grand Rounds, 2000

“Treatment of Atrial Fibrillation (Presentation and Case Discussion),” Friesinger Society Meeting , Vanderbilt University School of Medicine Cardiology Division Meeting at Sea Island, GA, 2001

“Device-based Clinical Trials: Design, Oversight, and Case Discussion (3 lectures),” Master of Science in Clinical Investigation, Drug and Device Development Course, Vanderbilt University School of Medicine, 2001

“AFFIRM and Other Trials: New Results in Atrial Fibrillation,” St Thomas Hospital, Nashville, 19th Annual Update in Cardiology, 2002

“Device-based clinical investigation: Special Issues in Trial Design and Regulation (extended lecture),” Master of Science in Clinical Investigation, Drug and Device Development Course, Vanderbilt University School of Medicine, June 2002

“Arrhythmia Panel Discussion” St Thomas Hospital, Nashville, 19th Annual Update in Cardiology, 2002

“Device-based clinical investigation: Special Issues in Trial Design and Regulation (extended lecture),” Master of Science in Clinical Investigation, Drug and Device Development Course, Vanderbilt University School of Medicine, June 2003

“Electrical noise in the environment: consequences for patients with pacemakers and defibrillators,” Interview, Fox news (TV), June 2003

“Evaluating cardiovascular physiology in mice,” Cardiology Grand Rounds, University of Pittsburgh, August 28, 2003

“Arrhythmogenic right ventricular cardiomyopthy,” Cardiovascular Medicine Conference, Vanderbilt University School of Medicine, October 14, 2003

“Learning from M&M: Treatment of stroke and prevention of no-reflow,” Cardiovascular Medicine Conference, Vanderbilt University School of Medicine, December 8, 2003

“Update in Atrial Fibrillation,” Cardiology Update 2004, Vanderbilt University School of Medicine / Page-Campbell Heart Institute, February 2004

“Atrial Fibrillation for Primary Care,” 21st Annual Primary Care Update, Vanderbilt University School of Medicine, May 22, 2004

“Medical Devices and Clinical Trials,” (extended lecture),” Master of Science in Clinical Investigation, Drug and Device Development Course, Vanderbilt University School of Medicine, June 14, 2004

“Progress Report: Cardiovascular Core, Vanderbilt Mouse Metabolic Phenotyping Center,” NIDDK Mouse Metabolic Phenotyping Centers Coordinating Meeting, U.T. Southwestern, September 7, 2004

“All those at High Risk of Sudden Cardiac Death Should Receive an ICD: Point/Counter-Point (with D. Darbar),” Cardiovascular Medicine Management Conference, Vanderbilt University School of Medicine, October 3, 2004

“The Other Ventricular Tachycardias,” Arrhythmia Core Curriculum, Vanderbilt University School of Medicine, February 24, 2005

“New Devices for a Difficult Patient Population: Heart Failure and ICD’s,” Cardiovascular Medicine Management Conference, Vanderbilt University School of Medicine, April 14, 2005

“Prediction, Prevention and Treatment of Sudden Cardiac Death,” Arrhythmia Core Curriculum, Vanderbilt University School of Medicine, June 15, 2005

“The 3 R’s of Medical Devices: Regulations, Registries, and Recalls,” Master of Science in Clinical Investigation, Drug and Device Development Course, Vanderbilt University School of Medicine, June 15, 2005

“Cardiac Stem Cells,” Cardiac Stem Cell Working Group, Division of Cardiovascular Medicine, Vanderbilt University School of Medicine, July 18, 2005

“Progress Report: Cardiovascular Core, Vanderbilt Mouse Metabolic Phenotyping Center,” NIDDK Mouse Metabolic Phenotyping Centers Coordinating Meeting, Yale, October 13, 2005

Session Chair, Novel Pacing Therapeutics, Heart Rhythm Society Meeting, May 2006

Session Chair, Controversies in Pacing, Heart Rhythm Society Meeting, May 2006

“Medical Device Investigation,” Master of Science in Clinical Investigation, Drug and Device Development Course, Vanderbilt University School of Medicine, June 2006

“Cardiovascular Phenotyping: The Mouse as a (Really) Little Human,” Autonomics Research Conference, Vanderbilt, February 6, 2007

“Sudden Cardiac Death and Primary Prevention ICD Therapy,” Update in Cardiology 2007, Nashville/Vanderbilt, Feb 23, 2007

“Arrhythmic Case Discussion,” Update in Cardiology 2007, Nashville/Vanderbilt, Feb 23, 2007

“Who doesn’t get an ICD? Who shouldn’t get an ICD? Cost effectiveness and device therapy.” Cardiology Clinical Management Conference, VUMC, March 2, 2007

“Cardiology and Metabolic Disease”. Cardiology Grand Rounds, Vanderbilt, April 2007

“Medical Device Investigation,” Master of Science in Clinical Investigation, Drug and Device Development Course, Vanderbilt University School of Medicine, June 2007

“Medical Device Investigation,” Master of Science in Clinical Investigation, Drug and Device Development Course, Vanderbilt University School of Medicine, June 2008

“When Good Devices Go Bad,” Department of Medicine Grand Rounds, Vanderbilt University School of Medicine, January 29, 2009

“Implantable Cardiac Defibrillators,” Cardiology Update 2009, Opryland Hotel (Nashville, VHVI), February 27, 2009

“Devices 2009,” Drug and Device Clinical Trials Course, Master of Science in Clinical Investigation, Vanderbilt University School of Medicine, June 2010

“Designing, Building and Installing a Machine to Prevent Death: Sudden Cardiac Death Intersession Course,” Vanderbilt University School of Medicine, October 14, 2009

“Devices 2010,” Drug and Device Clinical Trials Course, Master of Science in Clinical Investigation, Vanderbilt University School of Medicine, June 2010

“The need for long-term and reliable electrocardiographic recording in men (and mice),” Department of Biomedical Engineering, Chung Yuan University, Taipei, August 4, 2010

“Device Trials and Regulation,” Drug and Device Clinical Trials Course, Master of Science in Clinical Investigation, Vanderbilt University School of Medicine, June 2011

“Advisory Leads,” Miami Lead Management Symposium, Miami, Florida, June 11, 2011

“Update on Advisory Leads”, Eastern Lead Management Symposium, Miami, Florida, February 18, 2012

“The Extraction Environment,” Eastern Lead Management Symposium, Miami, Florida, February 18, 2012

“Device Research, Development and Regulation,” HHMI Clinical and Translational Scientist Development Program, Vanderbilt University School of Medicine, March 7, 2012

“Sudden Death: Reliable Prevention, and the Interactions with Industry,” Sudden Death Intersession Course, Vanderbilt University School of Medicine, October 16, 2012

“Advisory Leads,” U. Michigan Lead Symposium, Ann Arbor, Michigan, December 1, 2012

“An individual perspective on advisory leads,” Eastern Lead Management Symposium, Miami, Florida, February 9, 2013

“Management of Riata ICD leads,” American College of Cardiology, San Francisco, California, March 9, 2013

“Device Research, Development and Regulation,” MSCI Curriculum Core Lecture, Vanderbilt University School of Medicine, June 2014

“Point-Counterpoint: Extraction of Infected ICDs”, Miami Lead Management Symposium, Miami, Florida, March 14, 2014

“Riata Lead Update,” Miami Lead Management Symposium, Miami, Florida, March 15, 2014

“Device Research, Development and Regulation,” MSCI Curriculum Core Lecture, Vanderbilt University School of Medicine, June 2014

“Imaging Advisory Leads,” Meet the Experts, American Heart Association Scientific Sessions, Chicago, November 2014

“What’s new in Cardiac Implanted Electrical Devices: Update for Cardiac Anesthesia,” Cardiac Anesthesia Teaching Program, Vanderbilt University Medical Center, May 2015

“Recruitment for CSP 592 (i70 Trial),” VA Cooperative Study Program 592 Planning Meeting, Baltimore, MD, March 2015

“Device Research, Development and Regulation,” MSCI Curriculum Core Lecture, Vanderbilt University School of Medicine, June 24, 2015

“Poster Professor,” Cardiac Devices, American Heart Association Scientific Sessions, Orlando, FL, November 2015

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download